For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...

The Food and Drug Administration announced that branded tirzepatide, the active ingredient ... protocols for third-party lab ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide ... dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. The approval was based on ...

The FDA confirmed on Thursday that Eli Lilly’s tirzepatide, marketed as Zepbound for weight loss, is no longer in shortage, multiple outlets reported. The agency added that it will give compounders 60 ...

New Delhi: The pharmaceutical major Eli Lilly and Company (India) has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) ...

This year, that short rally may be an opportunity to take some profits, according to a four-decade Wall Street veteran and chart master Helene Meisler, who says all roads are leading to a ...

Now, with peptides, we can address the package to specific destinations with shared features, like every house with a red mailbox." Crossing the BBB is difficult because the structure has evolved ...